GlobalData on MSN
Novocure receives CE mark for Optune Pax device
The decision was based on findings from the Phase III PANOVA-3 clinical trial.
In a phase 3 trial, Optune Pax plus gem/nab-pac significantly improved median overall survival to 16.2 months vs 14.2 months with chemotherapy alone. The Food and Drug Administration (FDA) has ...
Last month, the United States Food and Drug Administration (FDA) approved a new wearable device for treating pancreatic cancer. This device, called Optune Pax, sends alternating electric fields to the ...
Zacks Investment Research on MSN
NovoCure's cancer treatment device option Pax gets European approval
NovoCure Limited NVCR recently announced that its portable medical device, Option Pax, has received the CE (Conformité ...
Carolyn Gusoff has covered some of the most high profile news stories in the New York City area and is best known as a trusted, tenacious, consistent and caring voice of Long Island's concerns. For ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results